Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Tumor-Agnostic 1

Conditions

Carcinoma, Non-Small-Cell Lung 3Ovarian Neoplasms 2Neoplasm Metastasis 2Lung Neoplasms 2Glioblastoma 2Breast Neoplasms 2Advanced Nonhematologic Malignancies 2Waldenstrom Macroglobulinemia 1Triple Negative Breast Neoplasms 1Recurrent Malignant Solid Neoplasm 1Non-hematologic Malignancy 1Neoplasms 1Multiple Myeloma 1Meningeal Neoplasms 1Malignant Neoplasms of Digestive Organs 1Lymphoma, Large-Cell, Anaplastic 1Hematologic Neoplasms 1Gliosarcoma 1Fibrolamellar hepatocellular carcinoma 1Fallopian Tube Neoplasms 1Brain Neoplasms 1Advanced Solid Tumors 1Advanced Solid Tumor 1Advanced Solid Malignancies 1Advanced Nonhematological Neoplasms 1Adenoma, Islet Cell 1

Interventions

pembrolizumab 82Paclitaxel 71Gemcitabine 66Carboplatin 61Cisplatin 46Docetaxel 44Bevacizumab 41Nivolumab 33Irinotecan 31Fluorouracil 29Pemetrexed 28Cyclophosphamide 26Cetuximab 26Capecitabine 26Erlotinib Hydrochloride 22venetoclax 21trametinib 21Leucovorin 20Sorafenib 17Albumin-Bound Paclitaxel 17Afatinib 17130-nm albumin-bound paclitaxel 17Topotecan 16Radiotherapy 16Oxaliplatin 16fludarabine 15regorafenib 14budigalimab 14atezolizumab 14Ipilimumab 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Neoplasms × sapanisertib × Clear all
NCT03017833 2023-10-04

Sapanisertib and Metformin in Treating Patients With Advanced or Metastatic Relapsed or Refractory Cancers

M.D. Anderson Cancer Center

Phase 1 Completed
31 enrolled
Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡